Table 1.

Activity of DPPIV in serum, % of CD26+ lymphocytes and % of CD26+ white blood cells, mean fluorescence intensity (MFI) of CD26 expression on lymphocytes and % of lymphocytes in healthy controls, people with vitiligo, patients with melanoma, and in patients with other malignant skin tumors and benign changes of the skin

Patients	n	DPPIV serum activity (IU/L)	% of CD26+ lymphocytes	% of CD26+ white blood cells	MFI of CD26 expression on lymphocytes	% of lymphocytes
Healthy controls	40	27.03 ± 7.00	50.33 ± 11.85	11.26 ± 5.26	278.41 ± 138.82	20.65 ± 8.48
Vitiligo	16	29.51 ± 7.24	48.04 ± 10.02	8.41 ± 3.30	690.29 ± 907.96	16.50 ± 4.51
Melanoma	64	21.81 ± 6.79 *	52.93 ± 10.77	7.16 ± 3.63 **	377.21 ± 554.38	13.43 ± 6.13 ***
Melanoma without metastatic disease	27	21.53 ± 6.74	53.24 ± 9.92	6.40 ± 3.28	409.51 ± 686.61	12.18 ± 5.91
Melanoma with metastatic disease	37	22.02 ± 6.91	52.71 ± 11.49	7.71 ± 3.81	353.64 ± 442.73	14.35 ± 6.19
Other malignant skin tumors	6	23.08 ± 8.28	47.17 ± 7.93	7.06 ± 3.28	235.73 ± 172.32	13.36 ± 6.02
Benign skin changes	6	27.32 ± 12.96	54.64 ± 10.78	9.19 ± 4.32	249.45 ± 237.82	15.77 ± 6.17

* p <0.0004 in comparison to healthy controls and to people with vitiligo.

** p < 0.00006 in comparison to healthy controls.

***p < 0.00003 in comparison to healthy controls.